ArticlePloS one2012
iNKT cells suppress the CD8+ T cell response to a murine Burkitt's-like B cell lymphoma.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 26 citations in OpenAlex.
- MutantFrontiers in immunology · 2026Article
- Glioblastoma-enriched glycosphingolipids modulate the function of human iNKT cells.Neuro-oncology · 2025Article
- Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses.JCI insight · 2022Article
- Invariant NKT Cells Promote the Development of Highly Cytotoxic Multipotent CXCR3Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- The Role of NKT Cells in Glioblastoma.Cells · 2021Review
- Unveiling the heterogeneity of NKT cells in the liver through single cell RNA sequencing.Scientific reports · 2020Article
- Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality.JCI insight · 2019Article
- Evolutionary Underpinnings of Innate-Like T Cell Interactions with Cancer.Immunological investigations · 2019Review
- Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy.Frontiers in immunology · 2019Article
- Altered Lipid Tumor Environment and Its Potential Effects on NKT Cell Function in Tumor Immunity.Frontiers in immunology · 2019Review
- Unique invariant natural killer T cells promote intestinal polyps by suppressing TH1 immunity and promoting regulatory T cells.Mucosal immunology · 2018Article
- The Yin and Yang of Invariant Natural Killer T Cells in Tumor Immunity-Suppression of Tumor Immunity in the Intestine.Frontiers in immunology · 2017Review
- Neurofibromin 1 Impairs Natural Killer T-Cell-Dependent Antitumor Immunity against a T-Cell Lymphoma.Frontiers in immunology · 2017Article
- Natural Killer T Cells in Cancer Immunotherapy.Frontiers in immunology · 2017Review
- Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?Oncotarget · 2016Review
- α-Galactosylceramide suppresses murine eosinophil production through interferon-γ-dependent induction of NO synthase and CD95.British journal of pharmacology · 2015Article
- NKT Cell Responses to B Cell Lymphoma.Medical sciences (Basel, Switzerland) · 2014Article
- The immunoregulatory role of type I and type II NKT cells in cancer and other diseases.Cancer immunology, immunotherapy : CII · 2014Review
- The function of the chemokine receptor CXCR6 in the T cell response of mice against Listeria monocytogenes.PloS one · 2014Article
- NKT cell networks in the regulation of tumor immunity.Frontiers in immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
The T cell response to B cell lymphomas differs from the majority of solid tumors in that the malignant cells themselves are derived from B lymphocytes, key players in immune response. B cell lymphomas are therefore well situated to manipulate their surrounding microenvironment to enhance tumor growth and minimize anti-tumor T cell responses. We analyzed the effect of T cells on the growth of a transplantable B cell lymphoma and found that iNKT cells suppressed the anti-tumor CD8(+) T cell response. Lymphoma cells transplanted into syngeneic wild type (WT) mice or Jalpha18(-/-) mice that specifically lack iNKT cells grew initially at the same rate, but only the mice lacking iNKT cells were able to reject the lymphoma. This effect was due to the enhanced activity of tumor-specific CD8(+) T cells in the absence of iNKT cells, and could be partially reversed by reconstitution of iNKT cells in Jalpha 18(-/-) mice. Treatment of tumor-bearing WT mice with alpha -galactosyl ceramide, an activating ligand for iNKT cells, reduced the number of tumor-specific CD8(+) T cells. In contrast, lymphoma growth in CD1d1(-/-) mice that lack both iNKT and type II NKT cells was similar to that in WT mice, suggesting that type II NKT cells are required for full activation of the anti-tumor immune response. This study reveals a tumor-promoting role for iNKT cells and suggests their capacity to inhibit the CD8(+) T cell response to B cell lymphoma by opposing the effects of type II NKT cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.